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Abstract 
Liquid biopsy is becoming a very popular sample obtaining procedure, replacing the invasive 
sampling methods for the diagnostic protocols. The advantages of this method include the 
possibility to isolate cell-free nucleic acids (cfNAs) for diagnostic or screening purposes. A 
comprehensive review combining all current and perspective applications of cell-free nucleic acids 
is missing. Published articles are dealing with one type of cfNAs, or discuss them from the 
perspective of single disorder. We collected here all known types of cfNAs which are known to be 
present in biological fluids and could be involved in further studies to find out the exact biological 
role of them in normal physiological and pathological conditions. Beyond doubt cfNAs will have a 
tremendous effect in future screening, diagnosis, prognosis, follow-up, and treatment of 
cardiovascular diseases, cancer, diabetes and other diseases. 
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1. Introduction 
The conventional tissue genotyping in cancer diagnosis is traditionally considered to be the 
standard method for identifying genomic alterations. However, this methodology is useless in the 
case of insufficient tumor tissue, and in follow up of treatments. Liquid biopsy based genotyping 
from serum/plasma or other body fluids coupled with advanced molecular technologies can 
provide non-invasive method for genetic analyses. These samples contain cell-free nucleic acids 
(cfNAs) which are valuable markers in different diagnostic protocols like prenatal diagnosis of 
genetic diseases, detection of cancer and cardiovascular diseases (Figure 1). 
2. History of cell-free nucleic acids 
CfNAs are present in biological fluids independent of the cells. They were first described by 
Mandel and Métais in 1948, but somehow their discovery was not noticed at that time.1 Almost 
twenty years later Tan et al observed high concentration of cfNAs in blood samples of patients with 
systemic lupus erythematosus.2 Steinman estimated the cfDNA concentration to be 10-30 ng/mL in 
healthy adults.3 Leon et al detected cfDNA in malignant diseases and they proposed to use it as a 
prognostic factor to determine the efficacy of cancer treatments. Unfortunately, at that time, 
molecular methods were not advanced enough for that purpose. Decreasing concentration of 
cfDNA was detected in those cancer patients who were cured.4 Later Sorenson et al isolated 
cell-free DNA from healthy individuals and cancer patients in 1994.5 In oncology cfNAs did not 
catch the attention of the scientists massively. It was different for prenatal diagnosis, when Lo et al 
demonstrated circulating fetal DNA (cffDNA) in the maternal plasma, detecting the presence of Y 
chromosome-specific DNA fractions and RhD in 1997, introducing a novel field in prenatal care – 
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the non-invasive prenatal diagnostics.6 Although aneuploidies determination from cffDNA was set 
as the ultimate goal in the field of non-invasive prenatal diagnosis, we had to wait another 18 years 
for the possibility of non-invasive detection of trisomy 21, until next-generation sequencing (NGS) 
technologies were introduced and became widely available.7 It opened a new horizon for wider use 
of NGS for other trisomies, subchromosomal aberations and even monogenic disorders. The 
success of use of NGS based sequencing of cffDNA in prenatal testing raised the interest of 
researchers and clinicians dealing with oncology, cardiovascular diseases etc. and there are 
numerous applications in the diagnosis of these diseases.8  
Most of the reviews about cfNAs deal only with DNAs, only few with RNAs (miRNA, ncRNA) or 
discuss it only from the aspect of a single disease or one type of cfNA. In contrast, there are 
numerous cell-free nucleic acid molecules participating in different physiological processes 
without knowing their exact physiological role yet. Experiments on graft hybrids have shown that 
cfNAs can go from somatic cells to germinal cells and thus transmit to offspring. This means that 
the acquisition of new features through cfNA is a reality and could contribute to evolution. Anker 
and Stroun lean on these facts and suggest that cfNAs may play a role in the evolution mechanism 
like Darwin's gemmules9. During our literature search, we realized that a comprehensive review of 
this field is missing and we collected the available information. CfNAs contain nuclear DNA, 
mitochondrial DNA (mtDNA) and various kinds of RNA molecules, which are listed in Table 1 
and Table 2. 
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3. Cell-free DNA 
Cell-free DNA (cfDNA) is highly fragmented molecule to the size of 166 bp, and there are other 
peaks observable on the electropherograms at around 300 bp and 450 bp size. Volik et al. reported 
that 90% of total cfDNA is present in low molecular weight band.10 Duque-Afonso et al. found that 
majority of cfDNA fragments range between 80 and 200 bp.11 Diehl et al. reported that the 
percentage of mutant molecules of APC gene in colorectal patients increased 5-20 fold and the 
average fragment size decreased. Enrichment of DNA fragments containing the mutant sequences 
were reported in cancer patients by several authors, it suggests that they could be used in diagnostic 
protocols. 12 
With idea to uncover the full diversity of cfDNA in the circulation, including ultrashort (<100 bp) 
dsDNA, ssDNA and dsDNA with nicks in both strands, Burnham et al. have applied a 
single-stranded DNA (ssDNA) library preparation method to sequenced the cfDNA in the plasma 
of lung transplant recipients13. This method yields a greater portion of sub-100 bp nuclear genomic 
cfDNA and an increased relative abundance of mitochondrial and microbial cfDNA. Furthermore, 
they found that the fragmentation profiles of microbial and mitochondrial DNA in plasma are 
highly similar, indicating that they are exposed to similar degradation processes.13 The origin of 
cfDNA is not fully explored, but there are many mechanisms by which the DNA can get into the 
circulation. The cfDNA fragments contain signals from which the tissue or cellular origin of this 
DNA can be derived. Using the analysis of these signals, it was proved that cfDNA in the blood 
plasma of healthy individuals is primarily lymphoid and myeloid origin.14 This is consistent with 
finding that main source of cfDNA is apoptosis of hematopoietic cells and the contribution from 
other tissues is minimal.15 In oncological patients, a major proportion of cfDNA is formed by 
apoptosis and necrosis of tumor cells, but the release of DNA from necrotic cells occurs only 
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through phagocytosis.16 In addition to cell death, neutrophils can mediate the immune response by 
releasing neutrophil extracellular traps (NETs) that can trap and kill various pathogens.17 These are 
extracellular network structures composed of both nuclear and mitochondrial DNA fibers, which 
are covered by various proteins such as histones and proteases.18 High levels of NETs have been 
shown to correlate with levels of circulating DNA, suggesting that DNA released from cells during 
NETosis is involved in the formation of circulating DNA.19 Another way of releasing DNA to the 
circulation is active release of newly synthesized DNA via vesicles and lipoproteonucleotide 
complexes.20 Based on the appearance in the circulation, cfDNA molecules can be divided into 
basic categories: free DNA fragments, vesicle-bound DNA and DNA-macromolecular complexes, 
which are described here. 
Free DNA fragments 
Free DNA fragments are naked sequences that are not bound to any other molecules or surface. 
During cell death, genomic DNA is cleaved and released into circulation, but only DNA that is 
associated with proteins can resist cleavage by DNase while free DNA fragments are cleaved until 
completely lost in body fluids.12 
Vesicle-bound DNA 
Nucleic acids can be contained in extracellular membrane vesicles (EMVs) where they are 
protected from degradation.21 These membrane structures mediate intercellular communication. 
Based on their size and origin, they are divided into exosomes, microvesicles and apoptotic bodies 
(ABs) (Table 3, Figure 2.). Vesicles can be released from both healthy and tumor cells. EMVs that 
are released from tumor cells contain various oncogenic factors in the form of oncoproteins and 
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nucleic acids and therefore have been named oncosomes. When oncosome is introduced into the 
recipient cell, these factors can transfer the phenotype of tumor cells to idle cells.22 
DNA-macromolecular complexes 
Circulating nucleosomes are DNA-protein complexes, that result from the cleavage of 
chromosomal DNA during apoptic cell death.23 These are double-stranded DNA fragments of 
180-200 bp that are wrapped around the octameric histone protein complex. Nucleosomes are 
linked to each other by 20-90 bp DNA and the sequence that is wrapped around the octamer is 147 
bp long.17 DNA that is directly bound to nucleosomes is protected from nuclease digestion, 
therefore in circulation it occurs in the form of mono- and oligo-nucleosome fragments.24 
Nucleosome spacing has been shown to vary between different cell types depending on 
tissue-specific gene expression. This is due to the fact that the nucleosomes are located near the 
start of transcription, at the sites where the transcription factors bind to the DNA. These factors 
protect the DNA from nuclease cleavage during apoptosis, resulting in a specific fragmentation 
pattern or transcription factor footprint that provides information about the tissue of origin of this 
cfDNA.12 
In the year 1978 Felgner et al. design DNA/cationic lipid complexes as a highly efficient 
transfection procedure. They show that lipid particles spontaneously interact with DNA through 
the electrostatic interaction and facilitates the delivery of functional DNA into the cells.25 It was 
shown that DNA/lipid complexes increased DNA half-life in plasma of mice, suggesting that lipids 
protect DNA from degradation.26 Thierry et al. propose that the formation of DNA/lipid complexes 
results from the universal tendency of nucleic acids to self-organize with cationic lipids and 
suggest possible existence of a ubiquitous self-organization of genetic materials.27 
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There are also macromolecular structures made of DNA and lipoproteins, that form complexes, 
called virtosomes. Lipoproteins bounded in virtosomes protect the nucleic acids from degradation 
by nucleases. Nucleic acids, proteins, and lipids involved in the formation of these complexes are 
newly synthesized molecules that synthetize at approximately the same time. Subsequently they 
are actively released from living cells and it is supposed that they play a role in intercellular 
communication.17 Virtosomes can enter the recipient cells, incorporate their DNA into the genome 
and subsequently modify the biology of these cells. These modifications include various 
immunological changes or transformation of normal cells into tumor cells. 
3.1. Cell-free mtDNA 
Mitochondria plays a central role in energy production, cell proliferation, and apoptosis. 
Mitochondrial genome is represented as 100-10,000 copies of circular molecules with the size of 
16569 bp. It codes 37 genes for 13 polypeptides of respiratory chain, 22 tRNA and 2 rRNA. 
Cell-free mitochondrial DNA (cf-mtDNA) analysis should take into account structural differences 
between mitochondrial and genomic DNA. Since mtDNA is a small molecule not protected by 
histones, it is clear that even cf-mtDNA fragments will be different.17 The size of cf-mtDNA in 
biological fluids, ranges from 30-80 bp with peaks in 42-60 bp and some authors report even higher 
size (Table 1).28 Like genomic DNA, mtDNA can also be transported by EMV. However, it is 
interesting that EMV can harbor full mitochondrial genome that can be transfered to cells with 
damaged metabolism and thus can restore their metabolic activity. On the other hand, it has been 
shown that such horizontal transfer of mtDNA by EMV can awaken dormant tumor cells and 
induce resistance to therapy.29 Variants and mtDNA copy number variations have been associated 
with various diseases including type-2 diabetes, atrial fibrillation, and cancer. It was demonstrated 
that these variations are a contributing factor to colorectal, breast and lung cancer and in addition, 
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these changes can be analyzed by cf-mtDNA.17.30 It suggest that cf-mtDNA analysis has the 
potential as a biomarker for some diseases. 
 
 
4. Cell-free RNA 
RNAs are relatively unstable molecules that are susceptible to degradation by ribonucleases.31 
Therefore, circulating cell-free RNAs (cfRNAs) are encapsulated within EMV or they form 
ribonucleoprotein complexes that protect them from nuclease activity.32,33 Even though cfRNA is 
relatively poorly studied, several studies have confirmed that they can be used as appropriate 
biomarkers for various diseases, including cancer.31 Several types of coding and non-coding 
cfRNAs, that are involved in the translation, processing and regulation of gene expression, are 
present in body fluids (Table 2). 
RNA in the circulation is protected from degradation by EMVs and ribonucleotide complexes, 
whereby molecules of nucleic acid are selectively packaged according to the viability and origin of 
the cells.33 During programmed cell death, ABs containing RNA, DNA, proteins and cellular 
organelles are released. ABs are the largest EMVs that are released from all types of cells, they are 
involved in phagocytosis, and play a role in horizontal transfer of oncogenes) (Table 3).33 In living 
cells, RNA is released via exosomes and microvesicles. Exosomes are the smallest EMVs, which 
could carry DNA, RNA, proteins and lipids and play a role in intercellular communication (Table 
3).34 Microvesicles are produced by the outward budding of the plasma membrane and they also 
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participate in intercellular communication and contain proteins, lipids, different RNAs and DNAs 
(Table 3).33 It was shown that circulating miRNA can bound to high-density lipoprotein (HDL) or 
RNA-binding proteins and it is supposed that these nucleoprotein complexes can be released from 
both living and dying cells.35 In addition to listed mechanisms, it has been reported that 
extracellular RNA of exogenous origin from food and human microbiome can get in to the 
circulation.36 
4.1. Protein-coding RNA 
Cell-free mRNA (cf-mRNA) is fragmented and less abundant so its detection is difficult. This is 
the reason, why majority of studies focus on the analysis of small non-coding RNAs, especially 
miRNA that are more stable and abundant, making their detection easier.37 However, despite of 
these limitations, the presence of extracellular mRNA in circulation of oncological patients was 
confirmed in 1999 and these results indicated that cf-mRNA may play an important role in the 
diagnosis and monitoring of cancer. It has been shown that the level of cf-mRNA is increased in 
oncology patients, and many studies have confirmed that cf-mRNA analysis can serve as a suitable 
marker for cancer.38 
4.2. Non-coding RNA 
Long non-coding RNA 
Long noncoding RNAs (lncRNAs) are transcripts with length more than 200 nucleotides that 
exhibit tissue-specific expression and are involved in epigenetic regulation.39 They have been 
shown to form a relatively stable secondary structure, therefore lncRNA are found in body fluids.40 
Some lncRNAs are selectively loaded into exosomes and can be transferred into other cells where 
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they modulate their functions and viability.41 In several studies, circulating lncRNAs have been 
described as suitable biomarkers for cardiovascular and tumor diseases.42 
MicroRNA 
MicroRNAs (miRNAs) are small single stranded non-coding RNA molecules with length of 18-24 
nucleotides. They are important regulators of gene expression, which play a key role in many 
biological processes.43 The regulation of gene expression by miRNA proceeds at the 
post-transcriptional level with the Argonaute 2 (AGO2) protein. It has been shown that 
extracellular miRNAs can be enclosed in exosomes but also can be associated with AGO2 protein 
or nucleomorphin 1 (NPM1) which protects them from degradation.35 Several studies have shown 
that most cell-free miRNA (cf-miRNA) is present in these ribonucleoprotein complexes and not in 
vesicular form.44 In addition to these proteins, RNA can be associated with HDL that is involved in 
intercellular communication. HDL carries miRNA molecules that can transport to recipient cells, 
where these miRNAs perform their regulatory function. Although the mechanism of association of 
HDL with miRNA is not investigated, it is clear that HDL protects bound miRNAs from RNase 
activity.45 Experimental studies suggest that the major source of circulating miRNAs in plasma are 
blood cells, where the level of these miRNAs largely depends on the total number of blood cells 
and hemolysis. These factors can change the level of known plasma cancerous miRNA biomarkers 
by up to 50-fold and should therefore be taken into account in the analyzes. 46  
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Transfer RNA 
Transfer RNAs (tRNAs) are 73-93 nucleotides long molecules, which transfer amino acids to the 
site of protein synthesis. By deep sequencing analysis, 30-33 nucleotides long tRNA fragments 
were identified in the blood serum of human and mice.47 Comparable results were also observed in 
serum of cattle where 28-40 nucleotide long tRNA fragments were identified, while 98.7% of 
circulating tRNAs ranged from 30 to 34 nucleotides.48 Most of circulating tRNA fragments contain 
the 5' end of tRNA, but only a trace amount of 3' tRNA fragments were detected. It was shown that 
most of these molecules was present in nucleoprotein complexes and originate from the 
hematopoietic and lymphoid tissues.49 Consequently, it is supposed that these circulating 5' tRNA 
fragments serve as signaling molecules involved in intercellular communication between 
hematopoietic and lymphoid tissues.50 Haussecker et al. suggest that tRNA fragments function as 
miRNA competitors and thus can affect RNA silencing and subsequently regulation of gene 
expression.51 
YRNA 
YRNA with length of 84-112 nucleotides belongs to a group of short non-coding molecules, that 
create stem-loop structures.50 These molecules associate with Ro60 and form ribonucleoprotein 
complexes, but their function is poorly studied.52 By deep sequencing, fragments of 27-33 
nucleotides derived from YRNA were identified in human blood serum and plasma. YRNA has 
been shown to undergo cleavage, resulting in stable fragments derived from the 5' end and less 
stable 3' fragments of the YRNA. Therefore, up to 95% of all detected YRNAs are fragments of the 
5' YRNA. In the circulation, these fragments were detected only in nucleoprotein form but not 
enclosed in exosomes or microvesicles. Further research is needed to verify whether changes in the 
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expression of individual YRNAs are associated with some diseases and can be used as 
biomarkers.47 
PIWI-interacting RNA 
Piwi-interacting RNAs (piRNAs) are short non-coding 26-31 nucleotide long RNA molecules, 
which mostly originate from genomic regions enriched with repetitive transposon sequences.49 
These molecules associate with the Argonaute protein PIWI to form a complex that plays a role in 
transposon silencing through CpG methylation, chromatin remodeling and RNA transcript 
degradation.54 In addition, piRNA is involved in gametogenesis, development and maintenance of 
germ cells and epigenetic regulation.55 It has been reported that piRNA also participates in the 
epigenetic regulation of cancer and various diseases.56 Several studies have confirmed that some of 
the piRNA molecules have altered expression in tumor tissue compared to healthy samples.57 It has 
been shown that piRNA is stable in blood serum and plasma inside of exosomes and it is thought 
that piRNA is also present in the form of nucleoprotein complexes as well as miRNA.58 Therefore, 
piRNA could serve as a valuable blood-based biomarker for the detection and monitoring of 
cancerous disease.56 
Circular RNA 
Circular RNAs (circRNAs) are endogenous noncoding RNA molecules that are very stable and 
evolutionarily conserved.59 These molecules exhibit tissue-specific expression, which also depends 
on the developmental stage. Sequence analysis has shown that more than 90% of circRNA 
originates from exon sequences and is likely to have an important function in post-transcriptional 
regulation of gene expression.35,60 This process is carried out in such a way that the circRNA 
complementarily binds to the miRNA molecules and thus affects their regulatory activity.61,62 
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Bioinformatic analysis has shown that circRNAs are not produced by chance, but genes coding for 
kinases are the most often subjected to circularization. Interestingly, in many cases circularization 
is more frequent than production of mRNA.63 circRNAs are located predominantly in the 
cytoplasm, but it has been shown that human serum contains a large number of intact and stable 
circRNA molecules. Like other RNAs, circRNA retains its biological activity in exosomes, which 
can be transferred to recipient cells. It has been reported that circRNAs are involved in the 
development of multiple diseases such as atherosclerosis, nervous system disorders or cancer.62 
Research on stomach and colon cancer has shown that circRNA released from tumor tissue can be 
used for diagnostic purposes and therefore appear to be potential biomarkers for cancer.62 
Other non-coding RNAs 
Most studies focus on miRNA and other short sequences are considered as degradation products of 
different RNAs so they are excluded from the analysis. However, some small non-coding RNAs 
have been shown to undergo processing to even smaller fragments that can perform various 
biological functions.65 In addition to listed types of RNA, other non-coding RNA molecules such 
as rRNA, snRNA and snoRNAs have been identified in human blood. However, these nucleic 
acids are present in amounts less than 1% of all small RNAs.47 This suggests that there are many 
other types of RNA molecules in human blood that could be valuable biomarkers for various 
diseases (Table 2). 
5. Future perspectives 
CfDNAs are already in the clinical practice as non-invasive prenatal testing (NIPT). A large 
portion of the invasive diagnostic sampling (amniocentesis and CVS) has already been replaced 
and the fetal loss and maternal psychological stress have been tremendously reduced. Fetal mRNA 
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based determinations were published (placental lactogen, human chorionic gonadotropin, 
chromosome 21 encoded mRNAs), they have also potential clinical application.8 
Diagnosis of monogenic disorders, prediction of congenital heart diseases, preeclampsia, 
intrauterine growth retardation and gestational diabetes using microRNAs or other non-coding 
RNAs are already in research phase and they could serve in the clinical practice soon. 
Tumor derived plasma cfNAs are available by liquid biopsy. Commercial kits produced by 
different manufacturers seems to provide valuable information to the clinicians for tumor 
classification and treatment monitoring. Plasma DNA tissue mapping or CancerLocator gives new 
perspectives in cancer diagnosis.66 More specific and sensitive platforms are under development, 
or in trial phase. Application of this technology revolutionizing cancer diagnosis and treatment. 
Cardiovascular diseases are the main cause of mortality and morbidity worldwide. CfNA based 
diagnostic methods give new avenue in their clinical use. There is an intensive research on this 
area, large population based studies are missing. Further new clinical application and expansion on 
this area will likely be developed. 
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Figure 1.  
Liquid biopsy scheme.  
Human blood contains cells; extracellular membrane vesicles (EMV); cell-free DNA (cfDNA); 
cell-free RNA (cfRNA) and proteins that can be used as biomarkers for various diseases. 
Figure 2.  
Formation of extracellular membrane vesicles (EMVs).  
Based on the size and origin, EMVs are divided into exosomes (40-100 nm), microvesicles 
(50-3000 nm) and ABs (800-5000 nm). EMVs are loaded with cellular content like nucleic acids 
and proteins. ABs as a product of apoptosis can also carry cellular organelles, e.g. nucleus, 
mitochondria, endoplasmatic reticulum (ER). 
 
